- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01946243
The Feasibility of Florbetapir Quantitation
June 1, 2015 updated by: Avid Radiopharmaceuticals
The Feasibility and Reliability of Utilizing Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Qualitative Interpretation of Amyvid Brain Scans
The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation.
The hypothesis is that the use of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.
Study Overview
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Readers have undergone Amyvid reader training
- Readers have minimal experience with quantitation of amyloid PET scans
Exclusion Criteria:
- Readers have previously been trained to quantitate amyloid PET scans
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Physician Readers
Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation.
No subjects will be exposed to Florbetapir F 18 as part of this study.
|
No Florbetapir F 18 will be administered in this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)
Time Frame: Scan acquired 50-60 min post-injection
|
Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers.
Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.
|
Scan acquired 50-60 min post-injection
|
Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)
Time Frame: Scan acquired 50-60 min post-injection
|
Evaluate whether the addition of quantitation as an adjunct to qualitative interpretations (VisQ) significantly improved the total accuracy of Amyvid scan interpretation in lower accuracy readers.
Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.
|
Scan acquired 50-60 min post-injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Accuracy (MIMNeuro Software, All Readers)
Time Frame: Scan acquired 50-60 min post-injection
|
Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone.
Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.
|
Scan acquired 50-60 min post-injection
|
Change in Reliability (MIMNeuro Software)
Time Frame: Scan acquired 50-60 min post-injection
|
Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretation alone.
The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.
|
Scan acquired 50-60 min post-injection
|
Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)
Time Frame: Scan acquired 50-60 min post-injection
|
Evaluate whether the total accuracy of Amyvid VisQ interpretation was non-inferior to the qualitative scan interpretation alone.
Only the 46 scans with autopsy from A07/A16 are used for this outcome measure.
|
Scan acquired 50-60 min post-injection
|
Change in Reliability (Siemens Syngo.PET Software)
Time Frame: Scan acquired 50-60 min post-injection
|
Evaluate whether VisQ interpretation significantly improved the reliability of Amyvid scan interpretation compared with qualitative scan interpretations alone.
The scan interpretation reliability will be evaluated using Fleiss' Kappa statistics.
|
Scan acquired 50-60 min post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
April 1, 2014
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
September 17, 2013
First Submitted That Met QC Criteria
September 18, 2013
First Posted (Estimate)
September 19, 2013
Study Record Updates
Last Update Posted (Estimate)
June 29, 2015
Last Update Submitted That Met QC Criteria
June 1, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18F-AV-45-QP01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimers Disease
-
Washington University School of MedicineEli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaboratorsRecruitingDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, Italy, Argentina, Australia, Brazil, Colombia, France, Germany, Ireland, Japan, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom
-
Washington University School of MedicineNational Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...RecruitingDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
-
Washington University School of MedicineEli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaboratorsCompletedDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
-
Washington University School of MedicineHoffmann-La Roche; Genentech, Inc.; National Institute on Aging (NIA); Alzheimer...SuspendedDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, Italy, France, Spain, Ireland, Argentina, Australia, Colombia, Germany, Mexico, Netherlands, Puerto Rico, United Kingdom
-
Northwestern UniversityPatient-Centered Outcomes Research InstituteCompletedAlzheimers, Falls, Aging in PlaceUnited States
-
BiogenTerminatedAlzheimers DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
Avid RadiopharmaceuticalsTerminatedAlzheimers DiseaseUnited States
-
University of AarhusCompleted
-
Hoffmann-La RocheRecruitingAlzheimers DiseaseKorea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Clinical Trials on Florbetapir F18
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Medical College of WisconsinTerminatedCardiac AmyloidosisUnited States
-
Samuel GandyCompletedTraumatic Brain Injury | Mild Cognitive Impairment | Chronic Traumatic EncephalopathyUnited States
-
Universidad Central del CaribeUniversity of Puerto RicoNot yet recruiting
-
Avid RadiopharmaceuticalsCompletedChronic Traumatic EncephalopathyUnited States
-
Avid RadiopharmaceuticalsCompletedFrontotemporal Dementia | Alzheimer's DiseaseUnited Kingdom
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States
-
St. Joseph's Hospital and Medical Center, PhoenixBanner Alzheimer's Institute, Phoenix; Translational Genomics Research Institute...CompletedDown Syndrome | Alzheimer's DementiaUnited States
-
Avid RadiopharmaceuticalsTerminated
-
Avid RadiopharmaceuticalsWithdrawnAlzheimer's DiseaseJapan